These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37126752)

  • 1. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.
    Andraka-Christou B; Simon KI; Bradford WD; Nguyen T
    Health Aff (Millwood); 2023 May; 42(5):658-664. PubMed ID: 37126752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.
    Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD
    Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
    Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
    JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.
    Nguemeni Tiako MJ; Dolan A; Abrams M; Oyekanmi K; Meisel Z; Aronowitz SV
    JAMA Netw Open; 2023 Jun; 6(6):e2318487. PubMed ID: 37318805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017.
    Huskamp HA; Riedel LE; Barry CL; Busch AB
    Med Care; 2018 Jun; 56(6):505-509. PubMed ID: 29668645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.
    Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R
    JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
    Shover CL
    Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
    [No Abstract]   [Full Text] [Related]  

  • 12. Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.
    Anderson KE; Saloner B; Eckstein J; Chaisson CE; Scholle SH; Niles L; Dy S; Alexander GC
    Med Care; 2021 May; 59(5):393-401. PubMed ID: 33734194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
    Andraka-Christou B
    Health Aff (Millwood); 2021 Jun; 40(6):920-927. PubMed ID: 34097509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 18. Common elements in opioid use disorder guidelines for buprenorphine prescribing.
    Atkinson TJ; Pisansky AJB; Miller KL; Yong RJ
    Am J Manag Care; 2019 Mar; 25(3):e88-e97. PubMed ID: 30875177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Buprenorphine Providers Requiring Cash Payment From Insured Women Seeking Opioid Use Disorder Treatment.
    Richards MR; Leech AA; Stein BD; Buntin MB; Patrick SW
    Med Care; 2023 Jun; 61(6):377-383. PubMed ID: 37083603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.